Literature DB >> 3224088

The prognostic and therapeutic value of second-look laparotomy in advanced ovarian cancer.

K Bertelsen1, M K Hansen, P H Pedersen, G Larsen, M Nyland, M Jacobsen, J E Andersen.   

Abstract

Of 267 patients with ovarian cancer FIGO stages III and IV, 157 underwent second-look laparotomy after combination chemotherapy consisting of cis-platinum and cyclophosphamide with and without doxorubicin. At second-look operation 45% had macroscopic tumour, 15% microscopic tumour, and 40% complete pathological response. Survival 3 years after second look was: complete pathological response 74%; microscopic disease 24%; visible tumour less than 1 cm 28%; visible tumour greater than 1 cm 17%; negative cytology 59%; and positive cytology 18%. Of the patients with macroscopic tumour, 29% had all visible tumour removed at second look. Three-year survival for these patients was about 45%.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3224088     DOI: 10.1111/j.1471-0528.1988.tb06811.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  3 in total

Review 1.  The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma.

Authors:  A E Selman; L J Copeland
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

2.  Continuous mitoxantrone infusion in pretreated epithelial ovarian cancer.

Authors:  M O Nicoletto; R Padrini; H Koussis; A Rosabian; S Aversa; L Endrizzi; P Azzoni; M Palumbo; M V Fiorentino
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.

Authors:  O Mogensen; B Mogensen; A Jakobsen
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.